Puberty blockers should stay on the table for some trans teens, national advice says, and two governments that banned them now have to answer
Australia's first national advice on puberty blockers says they should remain a clinical option for some trans and gender diverse young people who have started puberty, even though the evidence behind them is low certainty. The interim advice, opened for public comment at 1pm AEDT today, lands directly on Queensland and the Northern Territory, which have banned or restricted the drugs in their public systems. Within hours, both said their positions had not changed.
Live updates
- Monday afternoon AWSTLatest
Queensland Health Minister Tim Nicholls says the state's position is unchanged after its own independent review. A Northern Territory government spokesperson says the NT's position is also unchanged.
- 11.10am AWST
No public response yet from the Queensland or Northern Territory governments.
- 10am AWST
The NHMRC releases its interim advice on puberty suppressants for public consultation, open until 1pm AEDT on 18 January 2027.
This page checks for new updates automatically.
Three things to know
- The recommendation is "conditional": blockers could be considered after shared decisions between the young person, their carers and clinicians, not offered as routine.
- Reviewers found 15 non-randomised studies, most following patients for six months to two years, and rated the overall certainty of evidence as low.
- The advice is not binding, and Queensland and the Northern Territory have already said they will not change course. The full national guidelines are not due until late 2028.
The National Health and Medical Research Council’s interim advice on puberty suppressants for people under 18 was released for public consultation at 1pm AEDT (10am AWST) on Monday. Comments close at 1pm AEDT on 18 January 2027.
The advice was drawn up by the NHMRC’s Gender Guidelines Development Committee. It makes a conditional recommendation in favour of the drugs, known as GnRH analogues, for certain young people: those with gender incongruence, with or without distress, who have been assessed as suitable for treatment and have begun puberty.
A conditional recommendation means the benefits are judged likely to outweigh the harms, but the right choice depends on the individual. The committee said both triggers for that grading applied here: shared decision-making is essential, and the evidence is weak.
What did the evidence show?
The reviewers found the drugs may improve psychosocial functioning and may reduce suicidal behaviours. They found no eligible evidence either way on fertility, fractures or bone health. Serious adverse events were rare, the advice says, but young people on the medication should be monitored.
Why does it matter to Queensland and the NT?
Queensland paused new prescriptions of puberty blockers in its public system in January 2025 and, after a review, said in December 2025 the pause would continue until a UK clinical trial finishes, which is not expected until 2031. The Northern Territory has banned the drugs for under-18s in its public system.
The advice left both governments to decide whether to keep those restrictions. By Monday afternoon both had answered: no change.
Queensland Health Minister Tim Nicholls said the government had already held an independent review and “made a clear decision” on the treatments in public hospitals. “Our position remains unchanged,” he said. A Northern Territory government spokesperson said its position was also unchanged.
That sets the states against the national body for now. Federal Health Minister Mark Butler, who asked the NHMRC in 2025 to write the guidelines with priority advice on blockers, has said he expects the states to give the advice proper consideration.
Why is this so contested?
Supporters argue pausing puberty buys time for young people and their families. Critics say the treatment is experimental and that low-certainty evidence demands greater caution. The United Kingdom, Finland and many US states have moved to restrict use.
VNN will update this story as more is confirmed.
If this story raises concerns for you, support is available from Lifeline on 13 11 14, Beyond Blue on 1300 22 4636, QLife on 1800 184 527, or 13YARN on 13 92 76 for Aboriginal and Torres Strait Islander people.
How we got here
The key moments that brought this story into focus. Open any moment for detail.
January 2025Queensland pauses puberty blockers
New public-system prescriptions for under-18s are halted pending a review.
2025Butler orders national guidelines
The Health Minister asks the NHMRC for guidelines on trans and gender diverse young people, with priority advice on blockers.
December 2025Queensland extends its pause
The state says it will hold the line until a UK trial ends, expected in 2031.
16 November 2026National interim advice released
The NHMRC backs blockers as a conditional option and opens consultation.
16 November 2026Queensland and NT hold firm
Both governments say their positions are unchanged.
What happens next
Public consultation runs until 1pm AEDT on 18 January 2027. The NHMRC expects the full guidelines to go out for consultation by early 2028 and to be issued in late 2028. Queensland and the Northern Territory say they will keep their restrictions; Queensland's pause is set to run until 2031 unless the government changes it.
Sources
- VNN
VNN never names people who give us information in confidence. How we protect sources and tips.
That is the story in a minute. For the evidence, context and what happens next, switch to the full story.
We are reporting this as it happens. Details may change.
Weather today
Monday 16 November
Perth
Warm under grey skies · 10% rain
27°16°
A warm, grey Monday for Perth; heavy showers soak Brisbane and Singapore, Paris stays wet and London wakes cold but bright.
- Sydney18°15°
- Melbourne14°9°
- Brisbane28°20°
- Adelaide19°10°
- Auckland21°15°
- Singapore28°25°
More cities (13)
- Tokyo18°13°
- Hong Kong26°20°
- Mumbai32°23°
- Dubai30°20°
- Nairobi24°16°
- Lagos31°26°
- Johannesburg27°15°
- London7°4°
- Paris11°10°
- New York10°4°
- Los Angeles20°16°
- Toronto9°4°
- Sao Paulo25°19°
Highs and lows in °C, local time.
Breaking now
Live deskDeveloping stories
Live deskMost read this week
For subscribers
Read every subscriber story in full, on any device. Premium reports are sold separately.
Secure payment · Cancel anytime · Subscribers sign in
Markets
Stocks
- Alphabet (GOOGL)Nasdaq295.77 USDdown -0.98%
- Amazon (AMZN)Nasdaq266.66 USDdown -0.29%
- Apple (AAPL)Nasdaq356.27 USDup +0.39%
- ASX 200ASX9,082.20down -0.71%
- Berkshire Hathaway (BRK.B)NYSE592.94 USDup +0.53%
- BHP Group (BHP)ASX58.86 AUDdown -1.26%
Currencies
- AUD/EURForex0.613500 EURdown -0.29%
- AUD/GBPForex0.511800 GBPdown -0.47%
- AUD/JPYForex107.8800 JPYdown -0.85%
- AUD/NZDForex1.224200 NZDdown -0.25%
- AUD/USDForex0.675900 USDdown -0.66%
- BTC/USDCrypto68,241.00 USDdown -4.59%
As at 14 Nov 2026, 5:52 am GMT+0800. Entered by VNN. Not financial advice.
For you
Follow the topics you care about and save stories with the bookmark. They gather here, on this device only.
Saved on this device only. Nothing is sent to VNN.
Help keep the lights on.
Independent news costs money to make and nothing to read. Chip in and keep it that way.
ContributeFrom A$5 a month · Cancel anytimeThe daily briefing
Start informed.
The essential headlines, the useful context and what to watch next, in your inbox each morning.







Comments
0 commentsCommunity rules
To read and join the conversation, please agree to our rules.
You have agreed to the community rules.
No comments yet. Start the conversation.